Literature DB >> 28083317

Redirecting Innovation in U.S. Health Care: Options to Decrease Spending and Increase Value.

Steven Garber, Susan M Gates, Emmett B Keeler, Mary E Vaiana, Andrew W Mulcahy, Christopher Lau, Arthur L Kellermann.   

Abstract

New medical technologies are a leading driver of U.S. health care spending. This article identifies promising policy options to change which medical technologies are created, with two related policy goals: (1) Reduce total health care spending with the smallest possible loss of health benefits, and (2) ensure that new medical products that increase spending are accompanied by health benefits that are worth the spending increases. The analysis synthesized information from peer-reviewed and other literature, a panel of technical advisors convened for the project, and 50 one-on-one expert interviews. The authors also conducted case studies of eight medical products. The following features of the U.S. health care environment tend to increase spending without also conferring major health benefits: lack of basic scientific knowledge about some disease processes, costs and risks of U.S. Food and Drug Administration (FDA) approval, limited rewards for medical products that could lower spending, treatment creep, and the medical arms race. The authors identified ten policy options that would help advance the two policy goals. Five would do so by reducing the costs and/or risks of invention and obtaining FDA approval: (1) Enable more creativity in funding basic science, (2) offer prizes for inventions, (3) buy out patents, (4) establish a public-interest investment fund, and (5) expedite FDA reviews and approvals. The other five options would do so by increasing market rewards for products: (1) Reform Medicare payment policies, (2) reform Medicare coverage policies, (3) coordinate FDA approval and Centers for Medicare & Medicaid Services coverage processes, (4) increase demand for technologies that decrease spending, and (5) produce more and more-timely technology assessments.

Year:  2014        PMID: 28083317      PMCID: PMC5051971     

Source DB:  PubMed          Journal:  Rand Health Q        ISSN: 2162-8254


  15 in total

1.  Fostering Responsible Innovation in Health: An Evidence-Informed Assessment Tool for Innovation Stakeholders.

Authors:  Hudson P Silva; Andrée-Anne Lefebvre; Robson R Oliveira; Pascale Lehoux
Journal:  Int J Health Policy Manag       Date:  2021-03-14

2.  Economic evaluations of health technologies in Dutch healthcare decision-making: a qualitative study of the current and potential use, barriers, and facilitators.

Authors:  Kitty J Roseboom; Johanna M van Dongen; Emile Tompa; Maurits W van Tulder; Judith E Bosmans
Journal:  BMC Health Serv Res       Date:  2017-01-26       Impact factor: 2.655

3.  Beyond Adoption: A New Framework for Theorizing and Evaluating Nonadoption, Abandonment, and Challenges to the Scale-Up, Spread, and Sustainability of Health and Care Technologies.

Authors:  Trisha Greenhalgh; Joseph Wherton; Chrysanthi Papoutsi; Jennifer Lynch; Gemma Hughes; Christine A'Court; Susan Hinder; Nick Fahy; Rob Procter; Sara Shaw
Journal:  J Med Internet Res       Date:  2017-11-01       Impact factor: 5.428

4.  Maximising value from a United Kingdom Biomedical Research Centre: study protocol.

Authors:  Trisha Greenhalgh; Pavel V Ovseiko; Nick Fahy; Sara Shaw; Polly Kerr; Alexander D Rushforth; Keith M Channon; Vasiliki Kiparoglou
Journal:  Health Res Policy Syst       Date:  2017-08-14

5.  Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies.

Authors:  Pascale Lehoux; Fiona A Miller; Geneviève Daudelin; Jean-Louis Denis
Journal:  Int J Health Policy Manag       Date:  2017-09-01

6.  The Bright Elusive Butterfly of Value in Health Technology Development Comment on "Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies".

Authors:  Trisha Greenhalgh; Nick Fahy; Sara Shaw
Journal:  Int J Health Policy Manag       Date:  2018-01-01

7.  Medicare Cost Drivers during the 2004-2014 Health Accord Period in Canada: What Is the Evidence?

Authors:  Ruolz Ariste
Journal:  Healthc Policy       Date:  2018-02

8.  Weighing benefits and risks in aspects of security, privacy and adoption of technology in a value-based healthcare system.

Authors:  Edward Meinert; Abrar Alturkistani; David Brindley; Peter Knight; Glenn Wells; Nick de Pennington
Journal:  BMC Med Inform Decis Mak       Date:  2018-11-13       Impact factor: 2.796

9.  Analysing the role of complexity in explaining the fortunes of technology programmes: empirical application of the NASSS framework.

Authors:  Trisha Greenhalgh; Joe Wherton; Chrysanthi Papoutsi; Jenni Lynch; Gemma Hughes; Christine A'Court; Sue Hinder; Rob Procter; Sara Shaw
Journal:  BMC Med       Date:  2018-05-14       Impact factor: 8.775

10.  Vendor of choice and the effectiveness of policies to promote health information exchange.

Authors:  Anabel F Castillo; Marvin Sirbu; Alexander L Davis
Journal:  BMC Health Serv Res       Date:  2018-06-04       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.